TASIGNA200mg

TASIGNA (Nilotinib) 200mg hard capsules by Novartis is a powerful second-generation BCR-ABL tyrosine kinase inhibitor (TKI) that is approximately 30 times more potent than imatinib (Gleevec) against BCR-ABL in vitro. FDA-approved in 2007, Tasigna has become a cornerstone treatment for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Nilotinib works by selectively binding to the ATP-binding site of the BCR-ABL fusion protein — the oncogenic driver created by the Philadelphia chromosome translocation t(9;22). By blocking BCR-ABL kinase activity, nilotinib shuts down downstream signaling pathways essential for leukemic cell survival, leading to apoptosis and disease control. Tasigna is the first and only CML drug with FDA-approved treatment-free remission (TFR) data. In the ENESTfreedom and ENESTop studies, approximately 50% of patients who achieved sustained deep molecular response (MR4.5) could successfully discontinue treatment while maintaining remission — a groundbreaking achievement toward functional cure of CML. Working through licensed Turkish pharmacy channels, we provide authentic Novartis Tasigna with pricing confirmed in a written quote against a prescription within 24 hours for hospitals, hematology clinics, oncology centers, and pharmaceutical distributors worldwide. Contact us via WhatsApp for current pricing and availability.